Double‐blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment‐resistant depression

Mehdi, Syed Muhammad Ahsan; Atlas, Steven E.; Qadir, Sidra; Musselman, Dominique L.; Goldberg, Sharon; Woolger, Judi M.; Corredor, Raul G.; Abbas, Muhammad Hasan; Arosemena, Leopoldo; Caccamo, Simone; Campbell, Carmen Sílvia Grubert; Farooqi, Ashar; Gao, Jinrun; Konefal, Janet; Lages, Lucas C.; Lantigua, Laura A.; Lopez, J. E.; Padilla, V.; Rasul, Ammar; Ray, Anna M.; Simões, Herbert Gustavo; Tiozzo, Eduard; Lewis, John E.

doi:10.1111/pcn.12480

Cited by 13 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors observed significant differences in serum magnesium levels measured at two time points: baseline compared to day 8 (the last day of administration) and day 2 compared to day 8. However, depression rating scale results were not as substantial as the only difference seen was a reduction on the Patient Health Questionnaire-9 from baseline to day 7 [ 105 ]. This study was limited by its short duration of treatment.…”

Section: Resultsmentioning

confidence: 99%

The Role of Magnesium in Neurological Disorders

2018

View full text Add to dashboard Cite

Magnesium is well known for its diverse actions within the human body. From a neurological standpoint, magnesium plays an essential role in nerve transmission and neuromuscular conduction. It also functions in a protective role against excessive excitation that can lead to neuronal cell death (excitotoxicity), and has been implicated in multiple neurological disorders. Due to these important functions within the nervous system, magnesium is a mineral of intense interest for the potential prevention and treatment of neurological disorders. Current literature is reviewed for migraine, chronic pain, epilepsy, Alzheimer’s, Parkinson’s, and stroke, as well as the commonly comorbid conditions of anxiety and depression. Previous reviews and meta-analyses are used to set the scene for magnesium research across neurological conditions, while current research is reviewed in greater detail to update the literature and demonstrate the progress (or lack thereof) in the field. There is strong data to suggest a role for magnesium in migraine and depression, and emerging data to suggest a protective effect of magnesium for chronic pain, anxiety, and stroke. More research is needed on magnesium as an adjunct treatment in epilepsy, and to further clarify its role in Alzheimer’s and Parkinson’s. Overall, the mechanistic attributes of magnesium in neurological diseases connote the macromineral as a potential target for neurological disease prevention and treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

The Role of Magnesium in Neurological Disorders

2018

View full text Add to dashboard Cite

show abstract

“…Nonetheless, our findings were consistent with those of some other authors. Mehdi et al observed no changes in HDRS scores following magnesium supplementation in a group of participants ( n = 12) with mild-to-moderate treatment-resistant depression [ 50 ]. Similar results were observed in a randomized clinical study in a group of female patients with postpartum depression, where an 8-week treatment with magnesium at 320 mg/day failed to reduce the symptoms of depression evaluated with the Edinburgh Postnatal Depression Scale [ 51 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of Magnesium Supplementation on Unipolar Depression: A Placebo-Controlled Study and Review of the Importance of Dosing and Magnesium Status in the Therapeutic Response

Ryszewska-Pokraśniewicz¹,

Mach

Skalski

et al. 2018

Nutrients

View full text Add to dashboard Cite

Animal studies using tests and models have demonstrated that magnesium exerts an antidepressant effect. The literature contains few studies in humans involving attempts to augment antidepressant therapy with magnesium ions. The purpose of our study was to assess the efficacy and safety of antidepressant treatment, in combination with magnesium ions. A total of 37 participants with recurrent depressive disorder who developed a depressive episode were included in this study. As part of this double-blind study, treatment with the antidepressant fluoxetine was accompanied with either magnesium ions (120 mg/day as magnesium aspartate) or placebo. During an 8-week treatment period, each patient was monitored for any clinical abnormalities. Moreover, serum fluoxetine and magnesium levels were measured, and pharmaco-electroencephalography was performed. The fluoxetine + magnesium and fluoxetine + placebo groups showed no significant differences in either Hamilton Depression Rating Scale (HDRS) scores or serum magnesium levels at any stage of treatment. Multivariate statistical analysis of the whole investigated group showed that the following parameters increased the odds of effective treatment: lower baseline HDRS scores, female gender, smoking, and treatment augmentation with magnesium. The parameters that increased the odds of remission were lower baseline HDRS scores, shorter history of disease, the presence of antidepressant-induced changes in the pharmaco-EEG profile at 6 h after treatment, and the fact of receiving treatment augmented with magnesium ions. The limitation of this study is a small sample size.

show abstract

“…In addition, the Mg included in our infusions has also been suggested to improve mood in patients, although a recent randomized crossover trial of 4 g Mg (whereas our infusions typically have 1 g Mg) did not find any benefit in patients with treatment-resistant depression. 38 Future prospective studies that are randomized and controlled with strong statistical analyses will be necessary to better assess any potential benefits of IV AA in cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Retrospective Evaluation of Clinical Experience With Intravenous Ascorbic Acid in Patients With Cancer

et al. 2018

View full text Add to dashboard Cite

Background. Intravenous ascorbic acid (IV AA) has been used extensively in cancer patients throughout the United States. Currently, there are limited data on the safety and clinical effects of IV AA. The purpose of this study was to expand the current literature using a retrospective analysis of adverse events and symptomatic changes of IV AA in a large sample of cancer patients. Methods. We conducted a retrospective chart review of all patients receiving IV AA for cancer at the Thomas Jefferson University Hospital over a 7-year period. We assessed all reports of adverse events, laboratory findings, and hospital or emergency department admissions. We also reviewed quality-of-life data, including fatigue, nausea, pain, appetite, and mood. Results. There were 86 patients who received a total of 3034 doses of IV AA ranging from 50 to 150g. In all, 32 patients received only ascorbic acid as part of their cancer management (1197 doses), whereas 54 patients received ascorbic acid in conjunction with chemotherapy (1837 doses). The most common adverse events related to ascorbic acid were temporary nausea and discomfort at the injection site. All events reported in the ascorbic acid alone group were associated with less than 3% of the total number of infusions. Patients, overall, reported improvements in fatigue, pain, and mood while receiving ascorbic acid. Conclusions. The results of this retrospective analysis support the growing evidence that IV AA is generally safe and well tolerated in patients with cancer, and may be useful in symptom management and improving quality of life.

show abstract

Double‐blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment‐resistant depression

Cited by 13 publications

References 27 publications

The Role of Magnesium in Neurological Disorders

The Role of Magnesium in Neurological Disorders

Effects of Magnesium Supplementation on Unipolar Depression: A Placebo-Controlled Study and Review of the Importance of Dosing and Magnesium Status in the Therapeutic Response

Retrospective Evaluation of Clinical Experience With Intravenous Ascorbic Acid in Patients With Cancer

Contact Info

Product

Resources

About